- Home
- RVLV vs MIRM Comparison
RVLV vs MIRM Comparison
Compare RVLV & MIRM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RVLV
- MIRM
- Stock Information
- Founded
- RVLV 2003
- MIRM 2018
- Country
- RVLV United States
- MIRM United States
- Employees
- RVLV N/A
- MIRM N/A
- Industry
- RVLV Catalog/Specialty Distribution
- MIRM Biotechnology: Pharmaceutical Preparations
- Sector
- RVLV Consumer Discretionary
- MIRM Health Care
- Exchange
- RVLV Nasdaq
- MIRM Nasdaq
- Market Cap
- RVLV N/A
- MIRM 2.5B
- IPO Year
- RVLV 2019
- MIRM 2019
- Fundamental
- Price
- RVLV $21.37
- MIRM $50.30
- Analyst Decision
- RVLV Buy
- MIRM Strong Buy
- Analyst Count
- RVLV 15
- MIRM 9
- Target Price
- RVLV $26.20
- MIRM $66.22
- AVG Volume (30 Days)
- RVLV 1.2M
- MIRM 468.1K
- Earning Date
- RVLV 08-05-2025
- MIRM 08-06-2025
- Dividend Yield
- RVLV N/A
- MIRM N/A
- EPS Growth
- RVLV 106.68
- MIRM N/A
- EPS
- RVLV 0.71
- MIRM N/A
- Revenue
- RVLV $1,156,039,000.00
- MIRM $379,251,000.00
- Revenue This Year
- RVLV $7.71
- MIRM $35.83
- Revenue Next Year
- RVLV $7.64
- MIRM $16.83
- P/E Ratio
- RVLV $30.15
- MIRM N/A
- Revenue Growth
- RVLV 9.09
- MIRM 69.31
- 52 Week Low
- RVLV $14.88
- MIRM $33.52
- 52 Week High
- RVLV $39.58
- MIRM $54.23
- Technical
- Relative Strength Index (RSI)
- RVLV 54.29
- MIRM 59.09
- Support Level
- RVLV $19.93
- MIRM $47.89
- Resistance Level
- RVLV $21.93
- MIRM $51.93
- Average True Range (ATR)
- RVLV 0.86
- MIRM 1.49
- MACD
- RVLV 0.05
- MIRM -0.25
- Stochastic Oscillator
- RVLV 71.67
- MIRM 59.65
About MIRM Mirum Pharmaceuticals Inc.
Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.